1. Home
  2. NRO vs MOLN Comparison

NRO vs MOLN Comparison

Compare NRO & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neuberger Berman Real Estate Securities Income Fund Inc.

NRO

Neuberger Berman Real Estate Securities Income Fund Inc.

HOLD

Current Price

$3.06

Market Cap

199.6M

Sector

Finance

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.23

Market Cap

164.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NRO
MOLN
Founded
2003
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Finance/Investors Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
199.6M
164.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
NRO
MOLN
Price
$3.06
$4.23
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$3.75
AVG Volume (30 Days)
239.4K
4.3K
Earning Date
01-01-0001
03-05-2026
Dividend Yield
11.41%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$999.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.51
$3.36
52 Week High
$3.45
$5.81

Technical Indicators

Market Signals
Indicator
NRO
MOLN
Relative Strength Index (RSI) 56.61 48.40
Support Level $3.01 $4.11
Resistance Level $3.07 $4.28
Average True Range (ATR) 0.03 0.15
MACD 0.01 -0.01
Stochastic Oscillator 78.57 28.21

Price Performance

Historical Comparison
NRO
MOLN

About NRO Neuberger Berman Real Estate Securities Income Fund Inc.

NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: